• Auris Medical Holding Ltd (NASDAQ: EARS) has announced the publication of positive results from an in vivo study employing its OligoPhore technology in Adult T-cell Leukemia-Lymphoma (ATLL).

• The article was published in Nanomaterials, an international peer-reviewed open-access journal.

• Data demonstrated significant inhibition of tumor growth by siRNA knock-down of NF-κB utilizing the OligoPhore platform.

• The study demonstrated rapid delivery of siRNA to the tumor and significant reduction of target mRNA and protein expression, which altered the natural history of subsequent tumor progression.

• Tumor size, spleen size, and peripheral blood lymphocyte counts were significantly lower in treated mice than controls.

• Tumor growth was reduced to near zero in the most aggressive tumors.

• Further, the siRNA nanoparticles sensitized late-stage ATLL tumors to conventional chemotherapy with etoposide.

• ATLL is a rare and aggressive type of non-Hodgkin's lymphoma of mature T cells caused by the Human T-cell Leukemia / Lymphotropic Virus type 1 (HTLV 1).

• Price Action: EARS shares are up 12% at $3.72 during the market trading session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology

• Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.